{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T01:24:31Z","timestamp":1783819471533,"version":"3.55.0"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:00:00Z","timestamp":1721606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:00:00Z","timestamp":1721606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009687","name":"Uniwersytet Medyczny im. Piast\u00f3w Slaskich we Wroclawiu","doi-asserted-by":"publisher","award":["SUBZ.A460.24.040"],"award-info":[{"award-number":["SUBZ.A460.24.040"]}],"id":[{"id":"10.13039\/501100009687","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Heart failure (HF) is a systemic disease associated with a high risk of morbidity, mortality, increased risk of hospitalizations, and low quality of life. Therefore, effective, systemic treatment strategies are necessary to mitigate these risks. In this manuscript, we emphasize the concept of high-intensity care to optimize guideline-directed medical therapy (GDMT) in HF patients. The document highlights the importance of achieving optimal recommended doses of GDMT medications, including beta-blockers, renin\u2013angiotensin\u2013aldosterone inhibitors, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter inhibitors to improve patient outcomes, achieve effective, sustainable decongestion, and improve patient quality of life. The document also discusses potential obstacles to GDMT optimization, such as clinical inertia, physiological limitations, comorbidities, non-adherence, and frailty. Lastly, it also attempts to provide possible future scenarios of high-intensive care that could improve patient outcomes.<\/jats:p>","DOI":"10.1007\/s10741-024-10419-5","type":"journal-article","created":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T09:01:54Z","timestamp":1721638914000},"page":"1065-1077","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["High-intensity care for GDMT titration"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9977-7722","authenticated-orcid":false,"given":"Jan","family":"Biegus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Pagnesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Davison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Ponikowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Mebazaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gadi","family":"Cotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,22]]},"reference":[{"issue":"18","key":"10419_CR1","first-page":"e895","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR et al (2022) 2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 145(18):e895\u2013e1032","journal-title":"Circulation"},{"issue":"36","key":"10419_CR2","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, Burri H, Butler J, Celutkiene J, Chioncel O et al (2021) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42(36):3599\u20133726","journal-title":"Eur Heart J"},{"issue":"1","key":"10419_CR3","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/0735-1097(92)90167-L","volume":"20","author":"M Packer","year":"1992","unstructured":"Packer M (1992) The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 20(1):248\u2013254","journal-title":"J Am Coll Cardiol"},{"key":"10419_CR4","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ijcard.2021.10.149","volume":"345","author":"J Biegus","year":"2021","unstructured":"Biegus J, Nawrocka-Millward S, Zymlinski R, Fudim M, Testani J, Marciniak D, Rosiek-Biegus M, Ponikowska B, Guzik M, Garus M et al (2021) Distinct renin\/aldosterone activity profiles correlate with renal function, natriuretic response, decongestive ability and prognosis in acute heart failure. Int J Cardiol 345:54\u201360","journal-title":"Int J Cardiol"},{"issue":"5","key":"10419_CR5","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s10741-023-10325-2","volume":"28","author":"J Malgie","year":"2023","unstructured":"Malgie J, Clephas PRD, Brunner-La Rocca HP, de Boer RA, Brugts JJ (2023) Guideline-directed medical therapy for HFrEF: sequencing strategies and barriers for life-saving drug therapy. Heart Fail Rev 28(5):1221\u20131234","journal-title":"Heart Fail Rev"},{"issue":"3","key":"10419_CR6","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1002\/ehf2.13885","volume":"9","author":"T Hamada","year":"2022","unstructured":"Hamada T, Kubo T, Kawai K, Nakaoka Y, Yabe T, Furuno T, Yamada E, Kitaoka H, Ys Kochi (2022) Clinical characteristics and frailty status in heart failure with preserved vs. reduced ejection fraction. ESC Heart Fail 9(3):1853\u20131863","journal-title":"ESC Heart Fail"},{"issue":"1","key":"10419_CR7","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/ehf2.14163","volume":"10","author":"T Hamada","year":"2023","unstructured":"Hamada T, Kubo T, Kawai K, Nakaoka Y, Yabe T, Furuno T, Yamada E, Kitaoka H, Kochi YS (2023) Frailty interferes with the guideline-directed medical therapy in heart failure patients with reduced ejection fraction. ESC Heart Fail 10(1):223\u2013233","journal-title":"ESC Heart Fail"},{"issue":"3","key":"10419_CR8","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1002\/ehf2.14114","volume":"10","author":"T Abe","year":"2023","unstructured":"Abe T, Jujo K, Maeda D, Saito K, Ogasahara Y, Saito K, Saito H, Iwata K, Konishi M, Kitai T et al (2023) The interaction between physical frailty and prognostic impact of heart failure medication in elderly patients. ESC Heart Fail 10(3):1698\u20131705","journal-title":"ESC Heart Fail"},{"issue":"7","key":"10419_CR9","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1001\/jamacardio.2020.0640","volume":"5","author":"M Fiuzat","year":"2020","unstructured":"Fiuzat M, Ezekowitz J, Alemayehu W, Westerhout CM, Sbolli M, Cani D, Whellan DJ, Ahmad T, Adams K, Pina IL et al (2020) Assessment of limitations to optimization of guideline-directed medical therapy in heart failure from the GUIDE-IT trial: A secondary analysis of a randomized clinical trial. JAMA Cardiol 5(7):757\u2013764","journal-title":"JAMA Cardiol"},{"issue":"19","key":"10419_CR10","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1016\/j.jacc.2019.02.015","volume":"73","author":"SJ Greene","year":"2019","unstructured":"Greene SJ, Fonarow GC, DeVore AD, Sharma PP, Vaduganathan M, Albert NM, Duffy CI, Hill CL, McCague K, Patterson JH et al (2019) Titration of medical therapy for heart failure with reduced ejection fraction. J Am Coll Cardiol 73(19):2365\u20132383","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10419_CR11","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.jchf.2020.04.019","volume":"8","author":"M Jarjour","year":"2020","unstructured":"Jarjour M, Henri C, de Denus S, Fortier A, Bouabdallaoui N, Nigam A, O\u2019Meara E, Ahnadi C, White M, Garceau P et al (2020) Care gaps in adherence to heart failure guidelines: Clinical inertia or physiological limitations? JACC Heart Fail 8(9):725\u2013738","journal-title":"JACC Heart Fail"},{"issue":"11","key":"10419_CR12","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/j.jchf.2023.06.022","volume":"11","author":"SA Swat","year":"2023","unstructured":"Swat SA, Helmkamp LJ, Tietbohl C, Thompson JS, Fitzgerald M, McIlvennan CK, Harger G, Ho PM, Ahmad FS, Ahmad T et al (2023) Clinical inertia among outpatients with heart failure: Application of treatment nonintensification taxonomy to EPIC-HF trial. JACC Heart Fail 11(11):1579\u20131591","journal-title":"JACC Heart Fail"},{"issue":"4","key":"10419_CR13","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1002\/ehf2.14370","volume":"10","author":"M Novosadova","year":"2023","unstructured":"Novosadova M, Gianchetti L, Takagi K, Morishetty P, Gaeta L, Edwards C, Davison BA, Picod A, Mebazaa A, Cotter G (2023) Global differences in acute heart failure treatment: analysis of the STRONG-HF site feasibility questionnaire. ESC Heart Fail 10(4):2236\u20132247","journal-title":"ESC Heart Fail"},{"issue":"1","key":"10419_CR14","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/ehf2.14166","volume":"10","author":"KK Witte","year":"2023","unstructured":"Witte KK, Wachter R, Senni M, Belohlavek J, Straburzynska-Migaj E, Fonseca C, Lonn E, No\u00e8 A, Schwende H, Butylin D et al (2023) Influence of diabetes on sacubitril\/valsartan titration and clinical outcomes in patients hospitalized for heart failure. ESC Heart Fail 10(1):80\u201389","journal-title":"ESC Heart Fail"},{"issue":"21","key":"10419_CR15","doi-asserted-by":"publisher","first-page":"e031745","DOI":"10.1161\/JAHA.123.031745","volume":"12","author":"G Cotter","year":"2023","unstructured":"Cotter G, Davison BA, Lam CSP, Metra M, Ponikowski P, Teerlink JR, Mebazaa A (2023) Acute heart failure is a malignant process: But we can induce remission. J Am Heart Assoc 12(21):e031745","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"10419_CR16","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.jchf.2022.11.026","volume":"11","author":"J Harrington","year":"2023","unstructured":"Harrington J, Fonarow GC, Khan MS, Hernandez A, Anker S, Bohm M, Greene SJ, Felker GM, Vaduganathan M, Butler J (2023) Medication-attributable adverse events in heart failure trials. JACC Heart Fail 11(4):425\u2013436","journal-title":"JACC Heart Fail"},{"issue":"5","key":"10419_CR17","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1002\/ehf2.14455","volume":"10","author":"A Abdin","year":"2023","unstructured":"Abdin A, Komajda M, Borer JS, Ford I, Tavazzi L, Batailler C, Swedberg K, Rosano GMC, Mahfoud F, Bohm M et al (2023) Efficacy of ivabradine in heart failure patients with a high-risk profile (analysis from the SHIFT trial). ESC Heart Fail 10(5):2895\u20132902","journal-title":"ESC Heart Fail"},{"issue":"4","key":"10419_CR18","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.cardfail.2023.09.002","volume":"30","author":"D Tomasoni","year":"2024","unstructured":"Tomasoni D, Davison B, Adamo M, Pagnesi M, Mebazaa A, Edwards C, Arrigo M, Barros M, Biegus J, Celutkiene J et al (2024) Safety Indicators in Patients Receiving High-intensity Care After Hospital Admission for Acute Heart Failure: The STRONG-HF Trial. J Card Fail 30(4):525\u2013537","journal-title":"J Card Fail"},{"issue":"2","key":"10419_CR19","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.regg.2019.10.002","volume":"55","author":"A Esteban-Fernandez","year":"2020","unstructured":"Esteban-Fernandez A, Diez-Villanueva P, Vicent L, Bover R, Gomez-Bueno M, De Juan J, Iniesta AM, Garcia-Aguado M, Martinez-Selles M (2020) Sacubitril\/Valsartan is useful and safe in elderly people with heart failure and reduced ejection fraction. Data from a real-word cohort. Rev Esp Geriatr Gerontol 55(2):65\u201369","journal-title":"Rev Esp Geriatr Gerontol"},{"issue":"3","key":"10419_CR20","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1002\/ehf2.14317","volume":"10","author":"P Goyal","year":"2023","unstructured":"Goyal P, Zullo AR, Gladders B, Onyebeke C, Kwak MJ, Allen LA, Levitan EB, Safford MM, Gilstrap L (2023) Real-world safety of neurohormonal antagonist initiation among older adults following a heart failure hospitalization. ESC Heart Fail 10(3):1623\u20131634","journal-title":"ESC Heart Fail"},{"issue":"6","key":"10419_CR21","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1093\/ageing\/afz096","volume":"48","author":"P Monteiro","year":"2019","unstructured":"Monteiro P, Bergenstal RM, Toural E, Inzucchi SE, Zinman B, Hantel S, Kis SG, Kaspers S, George JT, Fitchett D (2019) Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME(R) trial. Age Ageing 48(6):859\u2013866","journal-title":"Age Ageing"},{"issue":"4","key":"10419_CR22","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1002\/ehf2.13929","volume":"9","author":"N Girerd","year":"2022","unstructured":"Girerd N, Von Hunolstein JJ, Pellicori P, Bayes-Genis A, Jaarsma T, Lund LH, Bilbault P, Boivin JM, Chouihed T, Costa J et al (2022) Therapeutic inertia in the pharmacological management of heart failure with reduced ejection fraction. ESC Heart Fail 9(4):2063\u20132069","journal-title":"ESC Heart Fail"},{"issue":"1","key":"10419_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ejhf.3109","volume":"26","author":"G Cotter","year":"2024","unstructured":"Cotter G, Davison BA, Adams KF Jr, Ambrosy AP, Atabaeva L, Beavers CJ, Bhatt AS, Givertz MM, Grodin JL, Lala A et al (2024) Effective medications can work only in patients who take them: Implications for post-acute heart failure care. Eur J Heart Fail 26(1):1\u20134","journal-title":"Eur J Heart Fail"},{"key":"10419_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.14687","author":"O Chioncel","year":"2024","unstructured":"Chioncel O, Celutkiene J, Belohlavek J, Kamzola G, Lainscak M, Merkely B, Milicic D, Nessler J, Ristic AD, Sawielajc L et al (2024) Heart failure care in the Central and Eastern Europe and Baltic region: Status, barriers, and routes to improvement. ESC Heart Fail. https:\/\/doi.org\/10.1002\/ehf2.14687","journal-title":"ESC Heart Fail"},{"issue":"12","key":"10419_CR25","doi-asserted-by":"publisher","first-page":"e1835","DOI":"10.1016\/S2214-109X(22)00432-6","volume":"10","author":"M Loeb","year":"2022","unstructured":"Loeb M, Roy A, Dokainish H, Dans A, Palileo-Villanueva LM, Karaye K, Zhu J, Liang Y, Goma F, Damasceno A et al (2022) Influenza vaccine to reduce adverse vascular events in patients with heart failure: a multinational randomised, double-blind, placebo-controlled trial. Lancet Glob Health 10(12):e1835\u2013e1844","journal-title":"Lancet Glob Health"},{"issue":"14","key":"10419_CR26","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1056\/NEJMoa0906431","volume":"361","author":"AJ Moss","year":"2009","unstructured":"Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, Estes NA 3rd, Foster E, Greenberg H, Higgins SL et al (2009) Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 361(14):1329\u20131338","journal-title":"N Engl J Med"},{"issue":"6","key":"10419_CR27","doi-asserted-by":"publisher","first-page":"3677","DOI":"10.1002\/ehf2.14559","volume":"10","author":"U Kocabas","year":"2023","unstructured":"Kocabas U, Ergin I, Kivrak T, Yilmaz Oztekin GM, Tanik VO, Ozdemir I, Avci Demir F, Dogdus M, Sen T, Altinsoy M et al (2023) Prognostic significance of medical therapy in patients with heart failure with reduced ejection fraction. ESC Heart Fail 10(6):3677\u20133689","journal-title":"ESC Heart Fail"},{"issue":"Suppl L","key":"10419_CR28","doi-asserted-by":"publisher","first-page":"L38","DOI":"10.1093\/eurheartjsupp\/suac120","volume":"24","author":"J Biegus","year":"2022","unstructured":"Biegus J, Moayedi Y, Saldarriaga C, Ponikowski P (2022) Getting ahead of the game: in-hospital initiation of HFrEF therapies. Eur Heart J Suppl 24(Suppl L):L38\u2013L44","journal-title":"Eur Heart J Suppl"},{"issue":"5","key":"10419_CR29","doi-asserted-by":"publisher","first-page":"3298","DOI":"10.1002\/ehf2.14051","volume":"9","author":"V Palin","year":"2022","unstructured":"Palin V, Drozd M, Garland E, Malik A, Straw S, McGinlay M, Simms A, Gatenby VK, Sengupta A, Levelt E et al (2022) Reduction of heart failure guideline-directed medication during hospitalization: prevalence, risk factors, and outcomes. ESC Heart Failure 9(5):3298\u20133307","journal-title":"ESC Heart Failure"},{"issue":"5","key":"10419_CR30","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1056\/NEJM199108013250501","volume":"325","author":"S Investigators","year":"1991","unstructured":"Investigators S, Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325(5):293\u2013302","journal-title":"N Engl J Med"},{"issue":"10","key":"10419_CR31","first-page":"1295","volume":"283","author":"A Hjalmarson","year":"2000","unstructured":"Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, Wikstrand J, El Allaf D, Vitovec J, Aldershvile J et al (2000) Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR\/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group JAMA 283(10):1295\u20131302","journal-title":"MERIT-HF Study Group JAMA"},{"issue":"9146","key":"10419_CR32","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","volume":"353","author":"Investigators, CIBIS-II","year":"1999","unstructured":"Investigators, CIBIS-II (1999) The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353(9146):9\u201313","journal-title":"Lancet"},{"issue":"22","key":"10419_CR33","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1056\/NEJM200105313442201","volume":"344","author":"M Packer","year":"2001","unstructured":"Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB et al (2001) Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344(22):1651\u20131658","journal-title":"N Engl J Med"},{"issue":"3","key":"10419_CR34","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","volume":"26","author":"MD Flather","year":"2005","unstructured":"Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat P et al (2005) Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26(3):215\u2013225","journal-title":"Eur Heart J"},{"issue":"14","key":"10419_CR35","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M et al (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348(14):1309\u20131321","journal-title":"N Engl J Med"},{"issue":"1","key":"10419_CR36","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B (2011) Group E-HS: Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364(1):11\u201321","journal-title":"N Engl J Med"},{"issue":"11","key":"10419_CR37","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K et al (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371(11):993\u20131004","journal-title":"N Engl J Med"},{"issue":"4","key":"10419_CR38","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","volume":"72","author":"SJ Greene","year":"2018","unstructured":"Greene SJ, Butler J, Albert NM, DeVore AD, Sharma PP, Duffy CI, Hill CL, McCague K, Mi X, Patterson JH et al (2018) Medical therapy for heart failure with reduced ejection fraction: The CHAMP-HF registry. J Am Coll Cardiol 72(4):351\u2013366","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10419_CR39","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jacc.2019.11.011","volume":"75","author":"TM Maddox","year":"2020","unstructured":"Maddox TM, Song Y, Allen J, Chan PS, Khan A, Lee JJ, Mitchell J, Oetgen WJ, Ponirakis A, Segawa C et al (2020) Trends in U.S. ambulatory cardiovascular care 2013 to 2017: JACC review topic of the week. J Am Coll Cardiol 75(1):93\u2013112","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10419_CR40","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/ejhf.2408","volume":"24","author":"A Kaplon-Cieslicka","year":"2022","unstructured":"Kaplon-Cieslicka A, Benson L, Chioncel O, Crespo-Leiro MG, Coats AJS, Anker SD, Filippatos G, Ruschitzka F, Hage C, Drozdz J et al (2022) A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction - insights from the ESC-HFA EORP heart failure long-term registry. Eur J Heart Fail 24(2):335\u2013350","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"10419_CR41","doi-asserted-by":"publisher","first-page":"e1008","DOI":"10.1016\/S2214-109X(18)30306-1","volume":"6","author":"TK Teng","year":"2018","unstructured":"Teng TK, Tromp J, Tay WT, Anand I, Ouwerkerk W, Chopra V, Wander GS, Yap JJ, MacDonald MR, Xu CF et al (2018) Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study. Lancet Glob Health 6(9):e1008\u2013e1018","journal-title":"Lancet Glob Health"},{"issue":"9","key":"10419_CR42","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1002\/ejhf.2271","volume":"23","author":"G Savarese","year":"2021","unstructured":"Savarese G, Bodegard J, Norhammar A, Sartipy P, Thuresson M, Cowie MR, Fonarow GC, Vaduganathan M, Coats AJS (2021) Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden). Eur J Heart Fail 23(9):1499\u20131511","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10419_CR43","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1002\/ehf2.14604","volume":"11","author":"PRD Clephas","year":"2024","unstructured":"Clephas PRD, Malgie J, Schaap J, Koudstaal S, Emans M, Linssen GCM, de Boer GA, van Heerebeek L, Borleffs CJW, Manintveld OC et al (2024) Guideline implementation, drug sequencing, and quality of care in heart failure: design and rationale of TITRATE-HF. ESC Heart Fail 11(1):550\u2013559","journal-title":"ESC Heart Fail"},{"key":"10419_CR44","doi-asserted-by":"crossref","unstructured":"Malgie J, Wilde MI, Clephas PRD, Emans ME, Koudstaal S, Schaap J, Mosterd A, van Ramshorst J, Wardeh AJ, van Wijk S et al (2024) Contemporary guideline-directed medical therapy in de novo, chronic, and worsening heart failure patients: First data from the TITRATE-HF study. Eur J Heart Fail","DOI":"10.1002\/ejhf.3267"},{"issue":"10244","key":"10419_CR45","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(20)30748-0","volume":"396","author":"M Vaduganathan","year":"2020","unstructured":"Vaduganathan M, Claggett BL, Jhund PS, Cunningham JW, Pedro Ferreira J, Zannad F, Packer M, Fonarow GC, McMurray JJV, Solomon SD (2020) Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet 396(10244):121\u2013128","journal-title":"Lancet"},{"issue":"2","key":"10419_CR46","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jchf.2021.09.004","volume":"10","author":"J Tromp","year":"2022","unstructured":"Tromp J, Ouwerkerk W, van Veldhuisen DJ, Hillege HL, Richards AM, van der Meer P, Anand IS, Lam CSP, Voors AA (2022) A systematic review and network meta-analysis of pharmacological treatment of heart failure with reduced ejection fraction. JACC Heart Fail 10(2):73\u201384","journal-title":"JACC Heart Fail"},{"issue":"4","key":"10419_CR47","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.jchf.2023.07.014","volume":"12","author":"S Zafeiropoulos","year":"2024","unstructured":"Zafeiropoulos S, Farmakis IT, Milioglou I, Doundoulakis I, Gorodeski EZ, Konstantinides SV, Cooper L, Zanos S, Stavrakis S, Giamouzis G et al (2024) Pharmacological treatments in heart failure with mildly reduced and preserved ejection fraction: Systematic review and network meta-analysis. JACC Heart Fail 12(4):616\u2013627","journal-title":"JACC Heart Fail"},{"key":"10419_CR48","doi-asserted-by":"crossref","unstructured":"Greene SJ, Ayodele I, Pierce JB, Khan MS, Lewsey SC, Yancy CW, Alhanti B, Van Spall HGC, Allen LA, Fonarow GC (2024) Eligibility and projected benefits of rapid initiation of quadruple medical therapy for newly diagnosed heart failure. JACC Heart Fail","DOI":"10.1016\/S0735-1097(24)02316-7"},{"issue":"27","key":"10419_CR49","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA et al (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37(27):2129\u20132200","journal-title":"Eur Heart J"},{"issue":"27","key":"10419_CR50","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1093\/eurheartj\/ehac210","volume":"43","author":"L Shen","year":"2022","unstructured":"Shen L, Jhund PS, Docherty KF, Vaduganathan M, Petrie MC, Desai AS, Kober L, Schou M, Packer M, Solomon SD et al (2022) Accelerated and personalized therapy for heart failure with reduced ejection fraction. Eur Heart J 43(27):2573\u20132587","journal-title":"Eur Heart J"},{"issue":"11","key":"10419_CR51","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1002\/ejhf.1575","volume":"21","author":"A Kimmoun","year":"2019","unstructured":"Kimmoun A, Cotter G, Davison B, Takagi K, Addad F, Celutkiene J, Chioncel O, Solal AC, Diaz R, Damasceno A et al (2019) Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP and GDF-15, of Heart Failure therapies (STRONG-HF): rationale and design for a multicentre, randomized, parallel-group study. Eur J Heart Fail 21(11):1459\u20131467","journal-title":"Eur J Heart Fail"},{"issue":"10367","key":"10419_CR52","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","volume":"400","author":"A Mebazaa","year":"2022","unstructured":"Mebazaa A, Davison B, Chioncel O, Cohen-Solal A, Diaz R, Filippatos G, Metra M, Ponikowski P, Sliwa K, Voors AA et al (2022) Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet 400(10367):1938\u20131952","journal-title":"Lancet"},{"issue":"2","key":"10419_CR53","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1001\/jamacardio.2023.4553","volume":"9","author":"G Cotter","year":"2024","unstructured":"Cotter G, Deniau B, Davison B, Edwards C, Adamo M, Arrigo M, Barros M, Biegus J, Celutkiene J, Cerlinskaite-Bajore K et al (2024) Optimization of evidence-based heart failure medications after an acute heart failure admission: A secondary analysis of the STRONG-HF randomized clinical trial. JAMA Cardiol 9(2):114\u2013124","journal-title":"JAMA Cardiol"},{"issue":"4","key":"10419_CR54","doi-asserted-by":"publisher","first-page":"e011221","DOI":"10.1161\/CIRCHEARTFAILURE.123.011221","volume":"17","author":"J Celutkiene","year":"2024","unstructured":"Celutkiene J, Cerlinskaite-Bajore K, Cotter G, Edwards C, Adamo M, Arrigo M, Barros M, Biegus J, Chioncel O, Cohen-Solal A et al (2024) Impact of rapid up-titration of guideline-directed medical therapies on quality of life: Insights from the STRONG-HF trial. Circ Heart Fail 17(4):e011221","journal-title":"Circ Heart Fail"},{"issue":"9","key":"10419_CR55","doi-asserted-by":"publisher","first-page":"e010599","DOI":"10.1161\/CIRCHEARTFAILURE.123.010599","volume":"16","author":"JA Ezekowitz","year":"2023","unstructured":"Ezekowitz JA, McMullan CJ, Westerhout CM, Pi\u00f1a IL, Lopez-Sendon J, Anstrom KJ, Hernandez AF, Lam CSP, O\u2019Connor CM, Pieske B et al (2023) Background medical therapy and clinical outcomes from the VICTORIA trial. Circ Heart Fail 16(9):e010599","journal-title":"Circ Heart Fail"},{"issue":"6","key":"10419_CR56","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1002\/ehf2.14524","volume":"10","author":"R Matsukawa","year":"2023","unstructured":"Matsukawa R, Okahara A, Tokutome M, Itonaga J, Koga E, Hara A, Kisanuki H, Sada M, Okabe K, Kawai S et al (2023) A scoring evaluation for the practical introduction of guideline-directed medical therapy in heart failure patients. ESC Heart Fail 10(6):3352\u20133363","journal-title":"ESC Heart Fail"},{"issue":"3","key":"10419_CR57","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ehf2.14705","volume":"11","author":"KP Kresoja","year":"2024","unstructured":"Kresoja KP, Adamo M, Rommel KP, Stolz L, Karam N, Giannini C, Melica B, von Bardeleben RS, Butter C, Horn P et al (2024) Guideline-directed medical therapy assessment in heart failure patients undergoing percutaneous mitral valve repair. ESC Heart Fail 11(3):1802\u20131807","journal-title":"ESC Heart Fail"},{"issue":"2","key":"10419_CR58","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/ejhf.1369","volume":"21","author":"W Mullens","year":"2019","unstructured":"Mullens W, Damman K, Harjola VP, Mebazaa A, Brunner-La Rocca HP, Martens P, Testani JM, Tang WHW, Orso F, Rossignol P et al (2019) The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 21(2):137\u2013155","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10419_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7326\/0003-4819-103-1-1","volume":"103","author":"GS Francis","year":"1985","unstructured":"Francis GS, Siegel RM, Goldsmith SR, Olivari MT, Levine TB, Cohn JN (1985) Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. Ann Intern Med 103(1):1\u20136","journal-title":"Ann Intern Med"},{"issue":"6","key":"10419_CR60","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1042\/cs0590443","volume":"59","author":"H Ikram","year":"1980","unstructured":"Ikram H, Chan W, Espiner EA, Nicholls MG (1980) Haemodynamic and hormone responses to acute and chronic frusemide therapy in congestive heart failure. Clin Sci (Lond) 59(6):443\u2013449","journal-title":"Clin Sci (Lond)"},{"issue":"8","key":"10419_CR61","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1002\/ejhf.2852","volume":"25","author":"J Biegus","year":"2023","unstructured":"Biegus J, Zymlinski R, Testani J, Fudim M, Cox ZL, Guzik M, Iwanek G, Hurkacz M, Raj D, Marciniak D et al (2023) The blunted loop diuretic response in acute heart failure is driven by reduced tubular responsiveness rather than insufficient tubular delivery. The role of furosemide urine excretion on diuretic and natriuretic response in acute heart failure. Eur J Heart Fail 25(8):1323\u20131333","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10419_CR62","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1038\/s41598-024-51744-x","volume":"14","author":"M Guzik","year":"2024","unstructured":"Guzik M, Iwanek G, Fudim M, Zymlinski R, Marciniak D, Ponikowski P, Biegus J (2024) Spot urine sodium as a marker of urine dilution and decongestive abilities in acute heart failure. Sci Rep 14(1):1494","journal-title":"Sci Rep"},{"issue":"10","key":"10419_CR63","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.ejheart.2007.07.011","volume":"9","author":"V Hasselblad","year":"2007","unstructured":"Hasselblad V, Gattis Stough W, Shah MR, Lokhnygina Y, O\u2019Connor CM, Califf RM, Adams KF Jr (2007) Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. Eur J Heart Fail 9(10):1064\u20131069","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"10419_CR64","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1016\/j.amjcard.2005.12.072","volume":"97","author":"S Eshaghian","year":"2006","unstructured":"Eshaghian S, Horwich TB, Fonarow GC (2006) Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol 97(12):1759\u20131764","journal-title":"Am J Cardiol"},{"issue":"5","key":"10419_CR65","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1002\/ehf2.14467","volume":"10","author":"G Baudry","year":"2023","unstructured":"Baudry G, Coutance G, Dorent R, Bauer F, Blanchart K, Boignard A, Chabanne C, Delmas C, D\u2019Ostrevy N, Epailly E et al (2023) Diuretic dose is a strong prognostic factor in ambulatory patients awaiting heart transplantation. ESC Heart Fail 10(5):2843\u20132852","journal-title":"ESC Heart Fail"},{"issue":"9","key":"10419_CR66","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1002\/ejhf.2967","volume":"25","author":"J Biegus","year":"2023","unstructured":"Biegus J, Fudim M, Salah HM, Heerspink HJL, Voors AA, Ponikowski P (2023) Sodium-glucose cotransporter-2 inhibitors in heart failure: Potential decongestive mechanisms and current clinical studies. Eur J Heart Fail 25(9):1526\u20131536","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10419_CR67","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/eurheartj\/ehac530","volume":"44","author":"J Biegus","year":"2023","unstructured":"Biegus J, Voors AA, Collins SP, Kosiborod MN, Teerlink JR, Angermann CE, Tromp J, Ferreira JP, Nassif ME, Psotka MA et al (2023) Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial. Eur Heart J 44(1):41\u201350","journal-title":"Eur Heart J"},{"issue":"1","key":"10419_CR68","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/ehf2.13665","volume":"9","author":"M Bohm","year":"2022","unstructured":"Bohm M, Assmus B, Anker SD, Asselbergs FW, Brachmann J, Brett ME, Brugts JJ, Ertl G, Wang A, Hilker L et al (2022) Less loop diuretic use in patients on sacubitril\/valsartan undergoing remote pulmonary artery pressure monitoring. ESC Heart Fail 9(1):155\u2013163","journal-title":"ESC Heart Fail"},{"issue":"3","key":"10419_CR69","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/ejhf.1402","volume":"21","author":"O Vardeny","year":"2019","unstructured":"Vardeny O, Claggett B, Kachadourian J, Desai AS, Packer M, Rouleau J, Zile MR, Swedberg K, Lefkowitz M, Shi V et al (2019) Reduced loop diuretic use in patients taking sacubitril\/valsartan compared with enalapril: the PARADIGM-HF trial. Eur J Heart Fail 21(3):337\u2013341","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10419_CR70","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/ejhf.2703","volume":"25","author":"S Chatur","year":"2023","unstructured":"Chatur S, Claggett BL, Vardeny O, Jering K, Desai AS, Pfeffer MA, Lefkowitz M, McMurray JJV, Solomon SD, Vaduganathan M (2023) Sacubitril\/valsartan and loop diuretic requirement in heart failure with preserved ejection fraction in the PARAGON-HF trial. Eur J Heart Fail 25(1):87\u201394","journal-title":"Eur J Heart Fail"},{"issue":"31","key":"10419_CR71","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1093\/eurheartj\/ehad283","volume":"44","author":"S Chatur","year":"2023","unstructured":"Chatur S, Vaduganathan M, Claggett B, Vardeny O, Desai AS, Jhund PS, de Boer RA, Lam CSP, Kosiborod MN, Shah SJ et al (2023) Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial. Eur Heart J 44(31):2930\u20132943","journal-title":"Eur Heart J"},{"key":"10419_CR72","doi-asserted-by":"crossref","unstructured":"Mebazaa A, Davison BA, Biegus J, Edwards C, Murtagh G, Varounis C, Hayrapetyan H, Sisakian H, Ter-Grigoryan VR, Takagi K et al (2024) Reduced congestion and improved response to a fluid\/sodium challenge in chronic heart failure patients after initiation of sacubitril\/valsartan: The NATRIUM-HF study. Eur J Heart Fail n\/a(n\/a)","DOI":"10.1002\/ejhf.3265"},{"key":"10419_CR73","doi-asserted-by":"crossref","unstructured":"Biegus J, Davison B, Cotter G, Edwards C, BCs, \u010celutkien\u0117 J, Chioncel O, Cohen-Solal A, Filippatos G, Novosadova M, Sliwa K, Adamo M, Arrigo M, Lam CSP, Ter Maaten JM, Deniau B, Barros M, \u010cerlinskait\u0117-Bajor\u0117 K, Damasceno A, Diaz R, Gayat E, Kimmoun A, Pang PS, Pagnesi M, Saidu H, MBBS, Takagi K, Tomasoni D, Voors AA, Metra M, Ponikowski P (2024) Effects of rapid up-titration of neurohormonal blockade on effective, sustainable decongestion and outcomes in STRONG-HF. J Am Coll Cardiol","DOI":"10.1016\/j.jacc.2024.04.055"},{"issue":"7","key":"10419_CR74","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1002\/ejhf.2916","volume":"25","author":"G Cotter","year":"2023","unstructured":"Cotter G, Davison B (2023) Acute heart failure is a remitting-relapsing disorder and not a step towards advanced heart failure: Implications for decongestion therapy. Eur J Heart Fail 25(7):933\u2013935","journal-title":"Eur J Heart Fail"},{"issue":"13","key":"10419_CR75","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.jacc.2024.01.029","volume":"83","author":"G Cotter","year":"2024","unstructured":"Cotter G, Davison B, Chioncel O (2024) Enhanced decongestive therapy in patients with acute heart failure: JACC review topic of the week. J Am Coll Cardiol 83(13):1243\u20131252","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10419_CR76","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/ehf2.14588","volume":"11","author":"M Abuelazm","year":"2024","unstructured":"Abuelazm M, Badr A, Turkmani M, Amin MA, Amin AM, Aboutaleb A, Gowaily I, Soliman Y, Abdelazeem B (2024) The efficacy and safety of new potassium binders on renin-angiotensin-aldosterone system inhibitor optimization in heart failure patients: a systematic review and meta-analysis. ESC Heart Fail 11(1):28\u201343","journal-title":"ESC Heart Fail"},{"issue":"4","key":"10419_CR77","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1002\/ehf2.13954","volume":"9","author":"S Takeuchi","year":"2022","unstructured":"Takeuchi S, Kohno T, Goda A, Shiraishi Y, Kawana M, Saji M, Nagatomo Y, Nishihata Y, Takei M, Nakano S et al (2022) Multimorbidity, guideline-directed medical therapies, and associated outcomes among hospitalized heart failure patients. ESC Heart Fail 9(4):2500\u20132510","journal-title":"ESC Heart Fail"},{"issue":"6","key":"10419_CR78","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1002\/ehf2.14097","volume":"9","author":"A Abdin","year":"2022","unstructured":"Abdin A, Schulz M, Riemer U, Had\u00ebri B, Wachter R, Laufs U, Bauersachs J, Kindermann I, Vukadinovi\u0107 D, B\u00f6hm M (2022) Sacubitril\/valsartan in heart failure: efficacy and safety in and outside clinical trials. ESC Heart Fail 9(6):3737\u20133750","journal-title":"ESC Heart Fail"},{"issue":"2","key":"10419_CR79","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/ejhf.3081","volume":"26","author":"D Tomasoni","year":"2024","unstructured":"Tomasoni D, Pagnesi M, Colombo G, Chiarito M, Stolfo D, Baldetti L, Lombardi CM, Adamo M, Maggi G, Inciardi RM et al (2024) Guideline-directed medical therapy in severe heart failure with reduced ejection fraction: An analysis from the HELP-HF registry. Eur J Heart Fail 26(2):327\u2013337","journal-title":"Eur J Heart Fail"},{"key":"10419_CR80","doi-asserted-by":"crossref","unstructured":"Cox Z, Zalawadiya S, Simonato M, Redfors B, Zhou Z, Kotinkaduwa L, Zile M, Udelson J, Lim DS, Grayburn PA et al (2022) Maximally tolerated guideline-directed medical therapy and barriers to optimization in patients with heart failure with reduced ejection fraction: the COAPT trial. Euro Heart J 43(Supplement_2):1","DOI":"10.1093\/eurheartj\/ehac544.975"},{"issue":"7","key":"10419_CR81","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.jchf.2023.03.009","volume":"11","author":"ZL Cox","year":"2023","unstructured":"Cox ZL, Zalawadiya SK, Simonato M, Redfors B, Zhou Z, Kotinkaduwa L, Zile MR, Udelson JE, Lim DS, Grayburn PA et al (2023) Guideline-Directed Medical Therapy Tolerability in Patients With Heart Failure and Mitral Regurgitation: The COAPT Trial. JACC Heart Fail 11(7):791\u2013805","journal-title":"JACC Heart Fail"},{"issue":"6","key":"10419_CR82","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1002\/ejhf.2206","volume":"23","author":"GMC Rosano","year":"2021","unstructured":"Rosano GMC, Moura B, Metra M, Bohm M, Bauersachs J, Ben Gal T, Adamopoulos S, Abdelhamid M, Bistola V, Celutkiene J et al (2021) Patient profiling in heart failure for tailoring medical therapy. A consensus document of the heart failure association of the european society of cardiology. Eur J Heart Fail 23(6):872\u2013881","journal-title":"Eur J Heart Fail"},{"issue":"19","key":"10419_CR83","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1016\/j.jacc.2019.03.464","volume":"73","author":"B Bozkurt","year":"2019","unstructured":"Bozkurt B (2019) Reasons for Lack of Improvement in Treatment With Evidence-Based Therapies in Heart Failure. J Am Coll Cardiol 73(19):2384\u20132387","journal-title":"J Am Coll Cardiol"},{"issue":"8 Pt 1","key":"10419_CR84","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.jchf.2023.05.013","volume":"11","author":"MR Mehra","year":"2023","unstructured":"Mehra MR, Nayak A, Desai AS (2023) Life-prolonging benefits of LVAD therapy in advanced heart failure: A clinician\u2019s action and communication aid. JACC Heart Fail 11(8 Pt 1):1011\u20131017","journal-title":"JACC Heart Fail"},{"issue":"6","key":"10419_CR85","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/ejhf.1378","volume":"21","author":"R Zymlinski","year":"2019","unstructured":"Zymlinski R, Sokolski M, Biegus J, Siwolowski P, Nawrocka-Millward S, Sokolska JM, Dudkowiak M, Marciniak D, Todd J, Jankowska EA et al (2019) Multi-organ dysfunction\/injury on admission identifies acute heart failure patients at high risk of poor outcome. Eur J Heart Fail 21(6):744\u2013750","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"10419_CR86","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1002\/ehf2.13859","volume":"9","author":"D Tomasoni","year":"2022","unstructured":"Tomasoni D, Vishram-Nielsen JKK, Pagnesi M, Adamo M, Lombardi CM, Gustafsson F, Metra M (2022) Advanced heart failure: guideline-directed medical therapy, diuretics, inotropes, and palliative care. ESC Heart Fail 9(3):1507\u20131523","journal-title":"ESC Heart Fail"},{"issue":"4","key":"10419_CR87","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.hfc.2021.06.001","volume":"17","author":"J Biegus","year":"2021","unstructured":"Biegus J, Niewinski P, Josiak K, Kulej K, Ponikowska B, Nowak K, Zymlinski R, Ponikowski P (2021) Pathophysiology of advanced heart failure: What knowledge is needed for clinical management? Heart Fail Clin 17(4):519\u2013531","journal-title":"Heart Fail Clin"},{"issue":"36","key":"10419_CR88","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1093\/eurheartj\/ehaa496","volume":"41","author":"M Serenelli","year":"2020","unstructured":"Serenelli M, Bohm M, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Solomon SD, DeMets DL et al (2020) Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). Eur Heart J 41(36):3402\u20133418","journal-title":"Eur Heart J"},{"issue":"48","key":"10419_CR89","doi-asserted-by":"publisher","first-page":"5006","DOI":"10.1093\/eurheartj\/ehac293","volume":"43","author":"M Metra","year":"2022","unstructured":"Metra M, Pagnesi M, Claggett BL, Diaz R, Felker GM, McMurray JJV, Solomon SD, Bonderman D, Fang JC, Fonseca C et al (2022) Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial. Eur Heart J 43(48):5006\u20135016","journal-title":"Eur Heart J"},{"key":"10419_CR90","doi-asserted-by":"crossref","unstructured":"Ambrosy AP, Chang AJ, Davison B, Voors A, Cohen-Solal A, Damasceno A, Kimmoun A, Lam CSP, Edwards C, Tomasoni D et al (2024) Titration of medications after acute heart failure is safe, tolerated, and effective regardless of risk. JACC Heart Fail 0(0)","DOI":"10.1016\/j.jchf.2024.04.017"},{"issue":"7","key":"10419_CR91","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1002\/ejhf.2920","volume":"25","author":"M Arrigo","year":"2023","unstructured":"Arrigo M, Biegus J, Asakage A, Mebazaa A, Davison B, Edwards C, Adamo M, Barros M, Celutkiene J, Cerlinskaite-Bajore K et al (2023) Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure in elderly patients: A sub-analysis of the STRONG-HF randomized clinical trial. Eur J Heart Fail 25(7):1145\u20131155","journal-title":"Eur J Heart Fail"},{"issue":"7","key":"10419_CR92","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1002\/ejhf.2882","volume":"25","author":"K Cerlinskaite-Bajore","year":"2023","unstructured":"Cerlinskaite-Bajore K, Lam CSP, Sliwa K, Adamo M, Ter Maaten JM, Leopold V, Mebazaa A, Davison B, Edwards C, Arrigo M et al (2023) Sex-specific analysis of the rapid up-titration of guideline-directed medical therapies after a hospitalization for acute heart failure: Insights from the STRONG-HF trial. Eur J Heart Fail 25(7):1156\u20131165","journal-title":"Eur J Heart Fail"},{"issue":"22","key":"10419_CR93","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1016\/j.jacc.2023.03.426","volume":"81","author":"M Pagnesi","year":"2023","unstructured":"Pagnesi M, Metra M, Cohen-Solal A, Edwards C, Adamo M, Tomasoni D, Lam CSP, Chioncel O, Diaz R, Filippatos G et al (2023) Uptitrating Treatment After Heart Failure Hospitalization Across the Spectrum of Left Ventricular Ejection Fraction. J Am Coll Cardiol 81(22):2131\u20132144","journal-title":"J Am Coll Cardiol"},{"issue":"31","key":"10419_CR94","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1093\/eurheartj\/ehad335","volume":"44","author":"M Adamo","year":"2023","unstructured":"Adamo M, Pagnesi M, Mebazaa A, Davison B, Edwards C, Tomasoni D, Arrigo M, Barros M, Biegus J, Celutkiene J et al (2023) NT-proBNP and high intensity care for acute heart failure: the STRONG-HF trial. Eur Heart J 44(31):2947\u20132962","journal-title":"Eur Heart J"},{"issue":"12","key":"10419_CR95","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1002\/ejhf.3074","volume":"25","author":"JM Ter Maaten","year":"2023","unstructured":"Ter Maaten JM, Mebazaa A, Davison B, Edwards C, Adamo M, Arrigo M, Barros M, Biegus J, Celutkiene J, Cerlinskaite-Bajore K et al (2023) Early changes in renal function during rapid up-titration of guideline-directed medical therapy following an admission for acute heart failure. Eur J Heart Fail 25(12):2230\u20132242","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"10419_CR96","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1002\/ejhf.3039","volume":"25","author":"O Chioncel","year":"2023","unstructured":"Chioncel O, Davison B, Adamo M, Antohi LE, Arrigo M, Barros M, Biegus J, Cerlinskaite-Bajore K, Celutkiene J, Cohen-Solal A et al (2023) Non-cardiac comorbidities and intensive up-titration of oral treatment in patients recently hospitalized for heart failure: Insights from the STRONG-HF trial. Eur J Heart Fail 25(11):1994\u20132006","journal-title":"Eur J Heart Fail"},{"key":"10419_CR97","doi-asserted-by":"crossref","unstructured":"Geert Voordes BD, Biegus J, Edwards C, Damman K, ter Maaten J, Mebazaa A, Takagi K, Adamo M, Ambrosy AP, Arrigo M, Barros M, Celutkiene J, \u010cerlinskait\u0117-Bajor\u0117 K, Chioncel O, Cohen-Solal A, Damasceno A, Deniau B, Diaz R, Filippatos G, Gayat E, Kimmoun A, Lam CSP, Metra M, Novosadova M, Pagnesi M, Pang P, Ponikowski P, Saidu H, Sliwa K, Tomasoni D, Cotter G, Voors A (2024) BIO-ADM as a marker for resiual congestion and early rehospitalization in patients hospitalized for acte heart failure; data from STRONG-HF. Euro J Heart Failure","DOI":"10.1002\/ejhf.3336"},{"issue":"1","key":"10419_CR98","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1002\/ehf2.14206","volume":"10","author":"KM Odegaard","year":"2023","unstructured":"Odegaard KM, Lirhus SS, Melberg HO, Hallen J, Halvorsen S (2023) Adherence and persistence to pharmacotherapy in patients with heart failure: a nationwide cohort study, 2014\u20132020. ESC Heart Fail 10(1):405\u2013415","journal-title":"ESC Heart Fail"},{"issue":"6","key":"10419_CR99","doi-asserted-by":"publisher","first-page":"3656","DOI":"10.1002\/ehf2.14358","volume":"10","author":"X Chen","year":"2023","unstructured":"Chen X, Kang Y, Dahlstrom U, Fu M (2023) Impact of adherence to guideline-directed therapy on risk of death in HF patients across an ejection fraction spectrum. ESC Heart Fail 10(6):3656\u20133666","journal-title":"ESC Heart Fail"},{"key":"10419_CR100","doi-asserted-by":"crossref","unstructured":"Huang W, Ahmed MM, Morris EJ, Yang L, O\u2019Neal L, Hernandez I, Bian J, Kimmel SE, Smith S, Guo J (2024) Trajectories of sacubitril\/valsartan adherence among medicare beneficiaries with heart\u00a0failure. JACC: Advances 0(0)","DOI":"10.1016\/j.jacadv.2024.100958"},{"issue":"41","key":"10419_CR101","doi-asserted-by":"publisher","first-page":"4374","DOI":"10.1093\/eurheartj\/ehac399","volume":"43","author":"M Packer","year":"2022","unstructured":"Packer M (2022) Potassium binders for patients with heart failure? The real enlightenment of the DIAMOND trial. Eur Heart J 43(41):4374\u20134377","journal-title":"Eur Heart J"},{"issue":"5","key":"10419_CR102","doi-asserted-by":"publisher","first-page":"2808","DOI":"10.1002\/ehf2.14022","volume":"9","author":"L Guasti","year":"2022","unstructured":"Guasti L, Dilaveris P, Mamas MA, Richter D, Christodorescu R, Lumens J, Schuuring MJ, Carugo S, Afilalo J, Ferrini M et al (2022) Digital health in older adults for the prevention and management of cardiovascular diseases and frailty. A clinical consensus statement from the ESC council for cardiology practice\/taskforce on geriatric cardiology, the ESC digital health committee and the esc working group on e-cardiology. ESC Heart Fail 9(5):2808\u20132822","journal-title":"ESC Heart Fail"},{"issue":"6","key":"10419_CR103","doi-asserted-by":"publisher","first-page":"3858","DOI":"10.1002\/ehf2.14056","volume":"9","author":"J Dauw","year":"2022","unstructured":"Dauw J, Sokolski M, Middleton JT, Nijst P, Dupont M, Forouzan O, Rothman AMK, Ruschitzka F, Flammer AJ, Mullens W (2022) Ambulatory haemodynamic-guided management reduces heart failure hospitalizations in a multicentre European heart failure cohort. ESC Heart Fail 9(6):3858\u20133867","journal-title":"ESC Heart Fail"},{"issue":"4","key":"10419_CR104","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1002\/ehf2.13956","volume":"9","author":"Y Kishino","year":"2022","unstructured":"Kishino Y, Kuno T, Malik AH, Lanier GM, Sims DB, Ruiz Duque E, Briasoulis A (2022) Effect of pulmonary artery pressure-guided therapy on heart failure readmission in a nationally representative cohort. ESC Heart Fail 9(4):2511\u20132517","journal-title":"ESC Heart Fail"},{"issue":"10394","key":"10419_CR105","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/S0140-6736(23)00923-6","volume":"401","author":"JJ Brugts","year":"2023","unstructured":"Brugts JJ, Radhoe SP, Clephas PRD, Aydin D, van Gent MWF, Szymanski MK, Rienstra M, van den Heuvel MH, da Fonseca CA, Linssen GCM et al (2023) Remote haemodynamic monitoring of pulmonary artery pressures in patients with chronic heart failure (MONITOR-HF): a randomised clinical trial. Lancet 401(10394):2113\u20132123","journal-title":"Lancet"},{"issue":"5","key":"10419_CR106","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.jchf.2015.11.011","volume":"4","author":"MR Costanzo","year":"2016","unstructured":"Costanzo MR, Stevenson LW, Adamson PB, Desai AS, Heywood JT, Bourge RC, Bauman J, Abraham WT (2016) Interventions linked to decreased heart failure hospitalizations during ambulatory pulmonary artery pressure monitoring. JACC Heart Fail 4(5):333\u2013344","journal-title":"JACC Heart Fail"},{"issue":"5","key":"10419_CR107","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1002\/ehf2.13978","volume":"9","author":"R Sabatier","year":"2022","unstructured":"Sabatier R, Legallois D, Jodar M, Courouve L, Donio V, Boudevin F, De Chalus T, Hauchard K, Belin A, Milliez P (2022) Impact of patient engagement in a French telemonitoring programme for heart failure on hospitalization and mortality. ESC Heart Fail 9(5):2886\u20132898","journal-title":"ESC Heart Fail"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-024-10419-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-024-10419-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-024-10419-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T09:30:54Z","timestamp":1723023054000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-024-10419-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,22]]},"references-count":107,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["10419"],"URL":"https:\/\/doi.org\/10.1007\/s10741-024-10419-5","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,22]]},"assertion":[{"value":"7 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"J.B. has received honoraria from Bayer, Boehringer Ingelheim, and AstraZeneca for lectures. J.B. is also an\u00a0 associate Editor of the Heart Failure Reviews. M.P. has received personal fees from Abbott Laboratories, AstraZeneca, Boehringer Ingelheim and Vifor Pharma. MA has received speaker fees from Abbott Vascular and Medtronic. A.M. has received grants from Roche Diagnostics, Abbott Laboratories, 4TEEN4, and Windtree Therapeutics; honoraria for lectures from Roche Diagnostics, Bayer, and MSD; is a consultant for Corteria Pharmaceuticals, S-form Pharma, FIRE-1, Implicity, 4TEEN4, and Adrenomed; and is coinventor of a patent on combination therapy for patients having acute or persistent dyspnoea. P.P. reports personal fees from Boehringer Ingelheim, AstraZeneca, Servier, Bristol Myers Squibb, Amgen, Novartis, Merck, Pfizer, Berlin Chemie, and grants and personal fees from Vifor Pharma. G.C. is employee of Momentum Research, which has received grants for research from Abbott Laboratories, Amgen, Celyad, Cirius Therapeutics, Corteria Pharmaceuticals, Heart Initiative, Sanofi, Windtree Therapeutics, and XyloCor Therapeutics. G.C. is director of Heart Initiative, a non-profit organization. G.C. is also an\u00a0 associate Editor of the Heart Failure Reviews. B.D. is employee of Momentum Research, which has received grants for research from Abbott Laboratories, Amgen, Celyad, Cirius Therapeutics, Corteria Pharmaceuticals, Heart Initiative, Sanofi, Windtree Therapeutics, and XyloCor Therapeutics. B.D. is director of Heart Initiative, a non-profit organization. B.D. is also an\u00a0 associate Editor of the Heart Failure Reviews.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}